The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 537-540

  Sane, Ramola ^a   Wu, Shu Pei ^a   Zhang, Rong ^a   Gallo, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; INTERSTITIAL FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PARTITION COEFFICIENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY EXCRETION; WILD TYPE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE KNOCKOUT TECHNIQUES; METHOTREXATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84896107281     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055228     Document Type: Article

References (34)

1. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147-155.
2. Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223-233.
3. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, and Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 40:1164-1169.
4. BelinskyMG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A,Westphal H, Shchaveleva I, Klein-Szanto A, and Gallo JM, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67:262-268. (Pubitemid 46142783)
5. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG; New Approaches to Brain Tumor Therapy (NABTT) Consortium (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51-58.
6. Bremnes RM, Slørdal L, Wist E, and Aarbakke J (1989) Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. Cancer Res 49:6359-6364. (Pubitemid 20000937)
7. Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, and Knipp GT (2010) ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol Pharm 7:1057-1068.
8. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150. (Pubitemid 34602407)
9. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054. (Pubitemid 36917926)
10. Cremers TI, de Vries MG, Huinink KD, van Loon JP, v d Hart M, Ebert B, Westerink BH, and De Lange EC (2009) Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J Neurosci Methods 178:249-254.
11. DeAngelis LM (2003) Primary central nervous system lymphoma: a curable brain tumor. J Clin Oncol 21:4471-4473.
12. Deeken JF and Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674. (Pubitemid 46952931)
13. Devineni D, Klein-Szanto A, and Gallo JM (1996) In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 38:499-507. (Pubitemid 26298352)
14. Gerstner E and Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticancer Ther 7:689-700. (Pubitemid 46805564)
15. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, and Gallo JM (2007) Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 43:1789-1795. (Pubitemid 46453073)
16. Jacot W, Gerlotto-Borne MC, Thezenas S, Pouderoux S, Poujol S, About M, and Romieu G (2010) Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 10:257.
17. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, and Sugiyama Y (2008) Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J Pharmacol Exp Ther 327:465-473.
18. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
19. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, and Raizer JJ (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78:255-260. (Pubitemid 44018818)
20. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, and Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621. (Pubitemid 39121487)
21. Li L, Agarwal S, and Elmquist WF (2013) Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos 41:659-667.
22. Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, and van Tellingen O (2013) Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res 19:2084-2095.
23. Liu X, Vilenski O, Kwan J, Apparsundaram S, and Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37:1548-1556.
24. Nierenberg D, Harbaugh R, Maurer LH, Reeder T, Scott G, Fratkin J, and Newman E (1991) Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery 28:752-761.
25. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, and Sugiyama Y (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37:315-321.
26. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524. (Pubitemid 26187339)
27. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
28. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603. (Pubitemid 34183923)
29. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, and Schinkel AH (2009) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350-3359.
30. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543. (Pubitemid 37139875)
31. Wang Z, Zhou Q, Kruh GD, and Gallo JM (2011) Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos 39:2155-2161.
32. Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, Rutkowski S, Warmuth-Metz M, and Kramm C (2011) High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol 102:433-442.
33. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133. (Pubitemid 44771928)
34. Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, and Batchelor TT (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-oncol 11:211-215.